+

WO2013033600A1 - Produit pharmaceutique et procédé d'analyse de l'exposition lumineuse d'un produit pharmaceutique - Google Patents

Produit pharmaceutique et procédé d'analyse de l'exposition lumineuse d'un produit pharmaceutique Download PDF

Info

Publication number
WO2013033600A1
WO2013033600A1 PCT/US2012/053450 US2012053450W WO2013033600A1 WO 2013033600 A1 WO2013033600 A1 WO 2013033600A1 US 2012053450 W US2012053450 W US 2012053450W WO 2013033600 A1 WO2013033600 A1 WO 2013033600A1
Authority
WO
WIPO (PCT)
Prior art keywords
photosensitive
active ingredient
property change
change
layer
Prior art date
Application number
PCT/US2012/053450
Other languages
English (en)
Inventor
Jeremy GUO
Deborah Shnek
Paula SPENCER
Li Sun
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to EA201490555A priority Critical patent/EA201490555A1/ru
Priority to CN201280041624.7A priority patent/CN103917458A/zh
Priority to MX2014002533A priority patent/MX2014002533A/es
Priority to AU2012301656A priority patent/AU2012301656A1/en
Priority to EP12769524.5A priority patent/EP2750989A1/fr
Priority to KR1020147008727A priority patent/KR20140058669A/ko
Priority to BR112014004591A priority patent/BR112014004591A2/pt
Priority to US14/241,882 priority patent/US20140315187A1/en
Priority to CA2840637A priority patent/CA2840637A1/fr
Publication of WO2013033600A1 publication Critical patent/WO2013033600A1/fr
Priority to ZA2013/09704A priority patent/ZA201309704B/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D79/00—Kinds or details of packages, not otherwise provided for
    • B65D79/02—Arrangements or devices for indicating incorrect storage or transport
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01D—MEASURING NOT SPECIALLY ADAPTED FOR A SPECIFIC VARIABLE; ARRANGEMENTS FOR MEASURING TWO OR MORE VARIABLES NOT COVERED IN A SINGLE OTHER SUBCLASS; TARIFF METERING APPARATUS; MEASURING OR TESTING NOT OTHERWISE PROVIDED FOR
    • G01D7/00—Indicating measured values
    • G01D7/005—Indication of measured value by colour change

Definitions

  • This patent is directed to a pharmaceutical product, and, in particular, to a pharmaceutical product with photosensitive properties, including a photosensitive device that defines the product in part and methods of using the photosensitive device in conjunction with the pharmaceutical product.
  • products may be exposed to visible and UV light sources during manufacturing, storage, and/or transportation, as well as during use in clinics and other healthcare facilities.
  • the products may be exposed to light sources during fill and finish
  • the products may be exposed when removed from the protective packaging in which they are stored prior to delivery, and may be exposed even at the time of delivery when diluted into solutions in clear IV bags as may occur when the product is delivered intravenously.
  • a pharmaceutical product includes a container having an exterior surface and an interior chamber, an active ingredient disposed in the interior chamber, the active ingredient having a photosensitive property that changes based on at least cumulative exposure to light having a wavelength within the range between X and Y, and a layer of photosensitive material disposed on the exterior surface of the container and exposed to environmental conditions contemporaneous with the active ingredient being disposed in the interior chamber.
  • the photosensitive material is reactive to light having a wavelength within the range between X and Y to experience a property change at a threshold of cumulative exposure to light received within the range between X and Y related to the change in the photosensitive property of the active ingredient.
  • a pharmaceutical product in another aspect of the present disclosure, includes a container having an interior chamber, the container constructed from a material that is photo-resistive, and a layer of photosensitive material disposed in the interior chamber of the container.
  • the photosensitive material is reactive to light having a wavelength within the range between X and Y to experience a property change at a threshold of cumulative exposure to light received within the range between X and Y related to the change in a photosensitive property of an active ingredient.
  • a pharmaceutical product in a further aspect of the present disclosure, includes a container having an exterior surface and an interior chamber, an active ingredient disposed in the interior chamber, the active ingredient having a
  • photosensitive property that changes based on at least cumulative exposure to light having a wavelength within the range between X and Y, and a label having a first region affixed to the exterior surface of the container with a layer of photosensitive material applied thereto and a second region removably attached to the exterior surface of the container with a layer of the photosensitive material applied thereto, the first and second regions exposed to environmental conditions contemporaneous with the active ingredient being disposed in the interior chamber.
  • the photosensitive material is reactive to light having a wavelength within the range between X and Y to experience a property change at a threshold of cumulative exposure to light received within the range between X and Y related to the change in the photosensitive property of the active ingredient.
  • a method of confirming correct handling of photo-sensitive material includes applying a layer of
  • the method also includes delivering the container to a recipient, collecting the container from the recipient, examining the layer of photosensitive to determine if the photosensitive material has experienced the property change, and identifying the container as mishandled if the photosensitive materials has experienced the property change.
  • a method of analyzing light exposure of a pharmaceutical product includes identifying a path for the
  • the pharmaceutical product within a facility comprising at least one space through which the pharmaceutical product passes, the pharmaceutical product comprising an active ingredient having a photosensitive property that changes based on at least cumulative exposure to light having a wavelength within the range between X and Y, and disposing at least one photosensitive device along the path, the at least one
  • the method also includes reading the at least one photosensitive device after being disposed along the path for evidence of the property change to the photosensitive material of the photosensitive device, and changing the path for the pharmaceutical product through the facility if the property change occurs to the photosensitive material of the photosensitive device.
  • FIG. 1 is a perspective view of a pharmaceutical product according to the present disclosure having a container with a layer of photosensitive material disposed on an exterior surface of the container;
  • FIG. 2 is a perspective view of another pharmaceutical product according to the present disclosure having a container with a layer of photosensitive material disposed on an exterior surface of the container;
  • Fig. 3 is a graph illustrating the color change of a layer of photosensitive material, as registered using a colorimeter, with increasing UV exposure;
  • Fig. 4 is a graph illustrating the color change of a layer of photosensitive material, as registered using a colorimeter, with increasing visible light exposure;
  • Fig. 5 is a graph illustrating one measure of the degradation of a protein exposed to visible light
  • Fig. 6 is a graph illustrating a measure of the degradation (% increase in high molecular weight species) of a monoclonal antibody polypeptide exposed to visible light, with reference to a color change of an associated layer of photosensitive material, as registered using a colorimeter;
  • Fig. 7 is a graph illustrating a measure of the degradation (yellow index) of a monoclonal antibody polypeptide exposed to visible light, with reference to a color change of an associated layer of photosensitive material, as registered using a colorimeter;
  • Fig. 8 is a graph illustrating a measure of the degradation (increase in basic peak for Cation Exchange-HPLC) of a monoclonal antibody polypeptide exposed to visible light, with reference to a color change of an associated layer of photosensitive material, as registered using a colorimeter;
  • Fig. 9 is a graph illustrating a measure of the degradation (increase in acidic peak for Cation Exchange-HPLC) of a monoclonal antibody polypeptide exposed to visible light, with reference to a color change of an associated layer of photosensitive material, as registered using a colorimeter;
  • Fig. 10 is a graph illustrating a measure of the degradation (absorption change) of a small molecule exposed to UV light, with reference to a color change of an associated layer of photosensitive material, as registered using a colorimeter;
  • Fig. 11 is a graph illustrating a measure of the degradation (yellow index) of a small molecule exposed to UV light, with reference to a color change of an associated layer of photosensitive material, as registered using a colorimeter;
  • Fig. 12 is a graph illustrating a measure of the degradation (% increase high molecular weight species) of a monoclonal antibody polypeptide exposed to UV light, with reference to a color change of an associated layer of photosensitive material, as registered using a colorimeter;
  • Fig. 13 is a graph illustrating a measure of the degradation (% increase low molecular weight species) of a monoclonal antibody polypeptide exposed to UV light, with reference to a color change of an associated layer of photosensitive material, as registered using a colorimeter;
  • Fig. 14 is a graph illustrating a measure of the degradation (yellow index) of an amino acid exposed to UV light, with reference to a color change of an associated layer of photosensitive material, as registered using a colorimeter;
  • Fig. 15 is a graph illustrating the color change of a layer of photosensitive material, as registered using a colorimeter, with increasing visible light exposure over a range of temperatures;
  • Fig. 16 is a perspective view of an alternative to the pharmaceutical product of Fig. 1;
  • Fig. 17 is a perspective view of a pharmaceutical product including an alternative label to that illustrated in Fig. 1, with a photo-resistive cover;
  • Fig. 18 is a perspective view of a pharmaceutical product including an alternative label to that illustrated in Fig. 1, with first and second detachable regions;
  • Fig. 19 is a perspective of a system including a product including the label of Fig. 18 and a syringe;
  • Fig. 20 is a perspective view of a pharmaceutical product including an alternative label to that illustrated in Fig. 1, with first and second detachable regions and a cover over the second region;
  • Fig. 21 is a perspective of a system including a product including the label of Fig. 20 and a syringe;
  • Fig. 22 is a perspective view of a pharmaceutical product including a primary label similar to that illustrated in Fig. 1, and a secondary label for
  • Fig. 23 is the product of Fig. 22, with the secondary label in a second state wherein the label has changed at least one characteristic to highlight that the product has been exposed to high temperatures;
  • FIG. 24 is a perspective view of another pharmaceutical product according to the present disclosure having a container with a layer of photosensitive material disposed within the container;
  • Fig. 25 is a graph of illustrating the color change of a layer of
  • Fig. 26 is a schematic diagram of a manufacturing plant layout wherein phototracking units according to the present disclosure have been disposed along a path, P, along which the pharmaceutical product passes within the manufacturing plant;
  • Fig. 27 is a graph illustrating changes in color of different sensitivities (in increasing order of sensitivity: “senl”, “sen2”, “sen3”, “sen4", “sen5") of
  • photosensitive material that may be used in the products, systems and methods disclosed herein, with increasing UV exposure;
  • Fig. 28 is a graph illustrating the color change of a layer of photosensitive material, as registered using a colorimeter, stored at 4°C compared with a control
  • Fig. 29 is a graph illustrating the color change of a layer of photosensitive material, as registered using a colorimeter, stored at 25°C compared with a control
  • Fig. 30 is a graph illustrating the color change of a layer of photosensitive material disposed inside and outside containers for a range of materials used in the fabrication of the container.
  • a pharmaceutical product includes a container having an exterior surface and an interior chamber, which interior chamber may be defined by an interior surface.
  • a material such as a polypeptide, may be disposed within the interior chamber, which material may be photosensitive and may experience degradation with exposure to light over a particular range of wavelengths.
  • a layer of photosensitive material may be disposed either on the exterior surface of the container or in the interior chamber, and may be exposed to environmental conditions contemporaneous with the polypeptide being disposed in the interior chamber, according to certain embodiments. According to other embodiments, the exposure of the layer of photosensitive material to environmental conditions may be delayed.
  • the photosensitive layer may be reactive to light of a particular wavelength so as to experience a property change at a threshold of cumulative exposure, which property change of the photosensitive layer may be related to the change in the photosensitive property of the polypeptide or other material.
  • the property change of the material defining the photosensitive layer can be a color change that is
  • colorimetrically detectable i.e., a color change that is detectable visually or by the use of colorimetric instrumentation.
  • a pharmaceutical product 100 is illustrated in Fig. 1 that includes a container 110 having an exterior surface 112 and an interior chamber 114, which chamber 114 may be defined by an interior surface 116.
  • the exterior surface 112 and the interior surface 116 may be defined by a wall 118 made of a single layer, or the surfaces 112, 116 may be defined by different layers of a multi-layered structure, for example.
  • the container 110 may be a glass vial having an open end 120 and a closed end 122, with the open end 120 including an opening formed at the end of a neck region 126 of reduced cross-section defined by a rim, which opening may be closed off by a rubber stopper held in place with a metal crimp ring or seal. While an exemplary
  • the container 110 may be made of polymeric materials, such as polycarbonate, polypropylene or Teflon, instead of glass.
  • the container 110 may be larger or smaller than the illustrated example, and have a different shape than that illustrated in Fig. 1.
  • the container 110 may be a larger container used for storage and transportation, such as a carboy (see Fig. 2), or a smaller container used for a single-dose treatment, such as a single-dose vial similar in structure but smaller in size than the container illustrated in Fig. 1.
  • the container also may have a non-rigid shape, such as in the form of a plastic bag, for example.
  • the pharmaceutical product 100 may also include a material disposed within the interior chamber 114 of the container 110.
  • the material disposed in the chamber 114 typically refers to (and thus includes) active ingredients, such as polypeptides, amino acids, and/or small molecules, and/or may also refer to (and thus include) an inactive ingredient or excipient in addition to the polypeptides, amino acids and/or small molecules.
  • Active ingredients may also include viruses, which viruses may contain cDNA or RNA encoded by glycoproteins and lipid layers.
  • the one or more active ingredients can be therapeutically active ingredients, stabilizing agents (e.g., amino acids), or diagnostic reagents, or a combination of therapeutic molecules, stabilizing agents, and/or diagnostic reagents.
  • the material disposed within the interior chamber 114 may be a material that has sensitivity to light. When the material is exposed to light, the light may change the characteristics of the material in the container. In certain cases, exposure to light may cause the material to degrade, and be less useful or cease to be useful for its intended purpose.
  • the material disposed in the interior chamber 114 of the container 110 may be a polypeptide. More particularly, the polypeptide may be suspended in an aqueous medium, and may be fluid (a liquid state) or frozen (a solid state).
  • the polypeptide may have, for example, a
  • photosensitive property that changes based on at least cumulative exposure to light having a wavelength within the range between X and Y. According to other embodiments, it may be desirable to monitor light exposure even when no
  • polypeptide and protein are used interchangeably herein and include a molecular chain of two or more amino acids linked covalently through peptide bonds.
  • the terms do not refer to a specific length of the product.
  • peptides and oligopeptides are included within the definition of polypeptide.
  • the terms include post-translational modifications of the polypeptide, for example, glycosylations, acetylations, biotinylations, 4-pentynoylations,
  • polypeptide PEGylations, phosphorylations and the like.
  • protein fragments, analogs, mutated or variant proteins, fusion proteins and the like are included within the meaning of polypeptide.
  • the terms also include molecules in which one or more amino acid analogs or non-canonical or unnatural amino acids are included as can be expressed recombinantly using known protein engineering techniques.
  • Non-limiting examples of materials that may be disposed in the interior chamber 114 may include darbepoetin alfa (such as Aranesp®), epoetin alfa (such as Epogen®), anakinra (Kineret®), pegfilgrastim (such as Neulasta®), denosumab (such as Prolia® or XGEVATM) and filgrastim (such as Neupogen®).
  • darbepoetin alfa such as Aranesp®
  • epoetin alfa such as Epogen®
  • anakinra such as Laineret®
  • pegfilgrastim such as Neulasta®
  • denosumab such as Prolia® or XGEVATM
  • filgrastim such as Neupogen®
  • Aranesp®, Epogen®, Kineret®, Neulasta®, Prolia®, XGEVATM and Neupogen® are manufactured by Amgen
  • products such as etanercept (such as Enbrel®), adalimumab (such as Humira®), infliximab (such as Remicade®), certolizumab pegol (such as Cimzia®), golimumab (such as Simponi®), abatacept (such as Orencia®), tocilizumab (such as Actemra®), panitumumab (such as
  • Vectibix® cetuximab (such as Erbitux®), trastuzumab (such as Herceptin®), bevacizumab (such as Avastin®), pegylated epoetin beta (such as Mircera ®), peginesatide (such as HematideTM) and rituximab (such as Rituxan®) may be disposed in the interior chamber 114.
  • cetuximab such as Erbitux®
  • trastuzumab such as Herceptin®
  • bevacizumab such as Avastin®
  • pegylated epoetin beta such as Mircera ®
  • peginesatide such as HematideTM
  • rituximab such as Rituxan®
  • Still further non-limiting examples include epoetin beta, epoetin zeta, epoetin theta, mogamulizumab, omalizumab (such as Xolair®), brodalumab, secukinumab, nimotuzumab, and ixekizumab.
  • the material disposed in the interior chamber 114 may include proteins with amino acid sequences identical to or substantially similar to all or part of one of the following proteins: a flt3 ligand (as described in International Application WO 94/28391, incorporated herein by reference), a CD40 ligand (as described in US Patent No. 6,087,329, incorporated herein by reference), erythropoeitin,
  • thrombopoeitin calcitonin, leptin, IL-2, angiopoietin-2 (as described by Maisonpierre et al. (1997), Science 277(5322): 55-60, incorporated herein by reference), Fas ligand, ligand for receptor activator of NF-kappa B (RANKL, as described in International Application WO 01/36637, incorporated herein by reference), tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, as described in International Application WO 97/01633, incorporated herein by reference), thymic stroma-derived lymphopoietin, granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor (GM-CSF, as described in Australian Patent No.
  • Fas ligand Fas ligand, ligand for receptor activator of NF-kappa B (RANKL, as described in International Application WO 01
  • mast cell growth factor a cell growth factor
  • stem cell growth factor described in e.g. US Patent No.6,204,363, incorporated herein by reference
  • epidermal growth factor keratinocyte growth factor, megakaryote growth and development factor
  • RANTES human fibrinogen-like 2 protein (FGL2; NCBI accession no. NM_00682; Riiegg and Pytela (1995), Gene 160: 257-62) growth hormone, insulin, insulinotropin, insulin-like growth factors, parathyroid hormone, interferons including a interferons, ⁇ interferon, and consensus interferons (such as those described in US Patent Nos.
  • exemplary proteins may include proteins comprising all or part of the amino acid sequence of a receptor for any of the above-mentioned proteins, an antagonist to such a receptor or any of the above-mentioned proteins, and/or proteins substantially similar to such receptors or antagonists.
  • receptors and antagonists include: both forms of tumor necrosis factor receptor (TNFR, referred to as p55 and p75, as described in US Patent No. 5,395,760 and US Patent No. 5,610,279, both of which are incorporated herein by reference), Interleukin- 1 (IL 1) receptors (types I and II; described in EP Patent No. 0 460 846, US Patent No. 4,968,607, and US Patent No. 5,767,064, all of which are incorporated herein by reference), IL-1 receptor antagonists (such as those described in US Patent No. 6,337,072,
  • IL-1 antagonists or inhibitors such as those described in US Patent Nos. 5,981,713, 6,096,728, and 5,075,222, all of which are incorporated herein by reference
  • IL-2 receptors such as those described in US Patent Nos. 5,981,713, 6,096,728, and 5,075,222, all of which are incorporated herein by reference
  • IL-4 receptors as described in EP Patent No. 0 367 566 and US Patent No. 5,856,296, both of which are incorporated by reference
  • IL-15 receptors such as those described in US Patent No. 0 367 566 and US Patent No. 5,856,296, both of which are incorporated by reference
  • IL-15 receptors such as those described in US Patent No. 0 367 566 and US Patent No. 5,856,296, both of which are incorporated by reference
  • IL-15 receptors such as those described in US Patent No. 0 367 566 and US Patent No. 5,856,296, both of which are incorporated by reference
  • IL-15 receptors such as
  • TRAIL receptors for TRAIL (including TRAIL receptors 1, 2, 3, and 4), and receptors that comprise death domains, such as Fas or Apoptosis-Inducing Receptor (AIR).
  • TRAIL including TRAIL receptors 1, 2, 3, and 4
  • AIR Apoptosis-Inducing Receptor
  • Still further exemplary proteins may include proteins comprising all or part of the amino acid sequences of differentiation antigens (referred to as CD proteins) or their ligands or proteins substantially similar to either of these.
  • CD proteins Such antigens are disclosed in Leukocyte Typing VI (Proceedings of the Vlth International Workshop and Conference, Kishimoto, Kikutani et al., eds., Kobe, Japan, 1996, which is incorporated by reference). Similar CD proteins are disclosed in subsequent workshops. Examples of such antigens include CD22, CD27, CD30, CD39, CD40, and ligands thereto (CD27 ligand, CD30 ligand, etc.).
  • CD antigens are members of the TNF receptor family, which also includes 4 IBB and OX40.
  • the ligands are often members of the TNF family, as are 4 IBB ligand and OX40 ligand.
  • enzymatically active proteins or their ligands may be included as part of the product 100.
  • proteins include proteins with all or part of one of the following proteins or their ligands or a protein substantially similar to one of these: metalloproteinase-disintegrin family members, various kinases, glucocerebrosidase, superoxide dismutase, tissue plasminogen activator, Factor VIII, Factor IX, apolipoprotein E, apolipoprotein A-I, globins, an IL-2 antagonist, alpha- 1 antitrypsin, TNF-alpha Converting Enzyme, ligands for any of the above-mentioned enzymes, and numerous other enzymes and their ligands.
  • the product 100 may include antibodies or portions thereof.
  • antibody includes reference to both glycosylated and non-glycosylated immunoglobulins of any isotype or subclass or to an antigen-binding region thereof that competes with the intact antibody for specific binding, unless otherwise specified, including human, humanized, chimeric, multi- specific, monoclonal, polyclonal, and oligomers or antigen binding fragments thereof.
  • Antibodies can be any class of immunoglobulin.
  • proteins having an antigen binding fragment or region such as Fab, Fab', F(ab')2, Fv, diabodies, Fd, dAb, maxibodies, single chain antibody molecules, complementarity determining region (CDR) fragments, scFv, diabodies, triabodies, tetrabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to a target polypeptide.
  • antibody is inclusive of, but not limited to, those that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from a host cell transfected to express the antibody.
  • the antibodies may include human antibodies, or portions thereof, as well as chimeric or humanized antibodies.
  • Chimeric antibodies include human constant antibody immunoglobulin domains coupled to one or more murine variable antibody immunoglobulin domain, fragments thereof, or substantially similar proteins.
  • Humanized antibodies include variable regions comprising framework portions of human origin and CDR portion from a non-human source.
  • the 100 product may also include conjugates of an antibody and a cytotoxic or luminescent substance. Such substances include: maytansine derivatives (such as DM1);
  • entero toxins such as a Staphlyococcal entero toxin
  • iodine isotopes such as iodine- 125
  • technium isotopes such as Tc-99m
  • cyanine fluorochromes such as Cy5.5.18
  • ribosome-inactivating proteins such as bouganin, gelonin, or saporin-S6
  • the product 100 may further include chimeric proteins selected in vitro to bind to a specific target protein and modify its activity such as those described in International Applications WO 01/83525 and WO 00/24782, both of which are incorporated by reference.
  • antibodies, in vitro- selected chimeric proteins, or antibody/cytotoxin or antibody/luminophore conjugates may include those that recognize any one or a combination of proteins including, but not limited to, the above-mentioned proteins and/or the following antigens: CD2, CD3, CD4, CD8, CDl la, CD14, CD18, CD20, CD22, CD23, CD25, CD33, CD40, CD44, CD52, CD80 (B7.1), CD86 (B7.2), CD147, IL-la, IL- ⁇ , IL-2, IL-3, IL-7, IL-4, IL-5, IL-8, IL-10, IL-2 receptor, IL-4 receptor, IL-6 receptor, IL-13 receptor, IL-18 receptor subunits, FGL2, PDGF- ⁇ and analogs thereof (such as those described in US Patent Nos.
  • VEGF vascular endothelial growth factor
  • TGF TGF-P2
  • TGF- ⁇ TGF- ⁇
  • EGF receptor including those described in US Patent No. 6,235,883 Bl, incorporated by reference
  • VEGF receptor hepatocyte growth factor
  • osteoprotegerin ligand interferon gamma
  • B lymphocyte stimulator BlyS, also known as BAFF, THANK, TALL-1, and zTNF4; see Do and Chen-Kiang (2002), Cytokine Growth Factor Rev.
  • C5 complement IgE, tumor antigen CA125, tumor antigen MUC1, PEM antigen, LCG (which is a gene product that is expressed in association with lung cancer), HER-2, a tumor-associated glycoprotein TAG-72, the SK-1 antigen, tumor-associated epitopes that are present in elevated levels in the sera of patients with colon and/or pancreatic cancer, cancer-associated epitopes or proteins expressed on breast, colon, squamous cell, prostate, pancreatic, lung, and/or kidney cancer cells and/or on melanoma, glioma, or neuroblastoma cells, the necrotic core of a tumor, integrin alpha 4 beta 7, the integrin VLA-4, B2 integrins, TRAIL receptors 1, 2, 3, and 4, RANK, RANK ligand, TNF-a, the adhesion molecule VAP-1, epithelial cell adhesion molecule (EpCAM), intercellular adhesion molecule 3 (ICAM
  • antibodies include, but are not limited to, adalimumab, bevacizumab, infliximab, abciximab, alemtuzumab, bapineuzumab, basiliximab, belimumab, briakinumab, canakinumab, certolizumab pegol, cetuximab, conatumumab, denosumab, eculizumab, gemtuzumab ozogamicin, golimumab, ibritumomab tiuxetan, labetuzumab, mapatumumab, matuzumab, mepolizumab, mogamulizumab, motavizumab, muromonab-CD3, natalizumab, nimotuzumab, ofatumumab, omalizumab, oregovomab, palivizumab, panitumumum
  • the product 100 may include an anti-idiotypic antibody or a substantially similar protein, including anti-idiotypic antibodies against: an antibody targeted to the tumor antigen gp72; an antibody against the ganglioside GD3; an antibody against the ganglioside GD2; or antibodies substantially similar to these.
  • the product 100 may include recombinant fusion proteins including any of the above-mentioned proteins.
  • recombinant fusion proteins including one of the above-mentioned proteins plus a multimerization domain such as a leucine zipper, a coiled coil, an Fc portion of an antibody, or a substantially similar protein, can be produced using the methods of the invention. See e.g. WO94/10308; Lovejoy et al. (1993), Science 259: 1288-1293; Harbury et al. (1993), Science 262: 1401-05; Harbury et al.
  • TNFR:Fc comprises the Fc portion of an antibody fused to an extracellular domain of TNFR, which includes amino acid sequences substantially similar to amino acids 1-163, 1-185, or 1-235 of Figure 2A of US Patent No. 5,395, 760, which is incorporated by reference.
  • RANK:Fc is described in International Application WO 01/36637, which is incorporated by reference.
  • the pharmaceutical product 100 illustrated in Fig. 1 includes a layer 140 of photosensitive material disposed on the exterior surface 112 of the container 110.
  • the photosensitive material may be reactive to light having a wavelength within the range between X and Y so as to experience a property change.
  • the color of the material may change, from yellow to green for example.
  • a non-limiting example of a photosensitive material that may be used in the layer 140 is available from UV Process Supply, Inc. of Chicago, Illinois under the UV FastCheckTM brand.
  • Fig. 3 illustrates a graph prepared relative to a photosensitive material that experiences a change in color (as exhibited by a change a colorimeter reading) with increasing UV exposure, the UV exposure occurring with a peak wavelength of about 350 to 370 nm and over a range of wavelengths about 315 to 400 nm (UVA).
  • Fig. 4 illustrates a graph prepared relative to a photosensitive material that experiences a change in color (as exhibited by a change in a colorimeter reading) with increasing visible light exposure, the visible light exposure occurring with a range of wavelengths from 401 to 750 nm.
  • a colorimeter such as the HunterLab UltraScan PRO colorimeter available from Hunter Associates Laboratory Inc. of Reston, Virginia, while a color reflection spectrodensitometer, such as the X-rite Model 530 available from X-rite Inc. of Grand Rapids, Michigan, may be used according to other embodiments.
  • the threshold of cumulative exposure to light received within the range between X and Y related to the property (e.g., color) change of the material in photosensitive layer 140 may be related to the change in the photosensitive property of the polypeptide or other material or substance disposed in the container 110.
  • the change in the photosensitive property of the polypeptide may be measured quantitatively using separation techniques such as chromatography, for example.
  • separation techniques such as chromatography, for example.
  • SEC size-exclusion
  • CEX cation-exchange
  • HIC hydrophobic-interaction
  • FIG. 5 shows the relationship between readings generated using HIC with an exemplary polypeptide exposed to visible light, with increasing HIC readings reflecting an increase in inactive species of the polypeptide with increased light exposure.
  • the graphs of Figs. 6-14 directly illustrate the relationship between (i) various measures of the degradation of monoclonal antibody polypeptides (as an example of a polypeptide), of quinine monohydrochloride dihydrate (as an example of a small molecule), or of tryptophan (as an example of an amino acid) with increasing visible light or UV light exposure and (ii) colorimeter readings of the color change of an associated layer of
  • Figs. 6-9, 12 and 13 relate to experiments performed with a monoclonal antibody
  • Figs. 10 and 11 relate to experiments performed with quinine monohydrochloride dihydrate (2% solution)
  • Fig. 14 relates to
  • Figs. 6- 9 relate to experiments performed using visible light
  • Figs. 10-14 relate to experiments performed using UV light. These experiments were conducted with light having a range of wavelengths between 190 to 1100 nm, with the UV exposure occurring with a peak wavelength of about 350 to 370 nm and principally over a range of wavelengths from about 315 to 400 nm (UVA) and the visible light exposure occurring principally over a range of wavelengths from about 401 to 750 nm.
  • UVA 315 to 400 nm
  • the color of the layer of photosensitive material was measured using an X-Rite spectodensitometer (manufactured by X-Rite of Grand Rapids, Michigan), which device is exemplary of the types of color-measuring equipment that may be used in such an experimental set-up.
  • X-Rite spectodensitometer manufactured by X-Rite of Grand Rapids, Michigan
  • a high molecular weight species is typically in the form of aggregates that may lead to immunogenic reactions or adverse events upon administration, while a low molecular weight species is typically in the form of degradants.
  • a Ultrascan® PRO spectrophotometer manufactured by Hunter Associates Labs., Inc.
  • the measure of the degradation of the sample also increases with increasing light exposure. That is an increase in high or low molecular weight species is reflective of degradation of the mAb polypeptide (Figs. 6, 12, 13), as would be an increase in the acidic or basic peak produced using Cation Exchange-HPLC (Figs. 8, 9) representing a change in the charged species.
  • an increase in the yellow index (Figs. 7, 11) is reflective of degradation of the mAb polypeptide, the small molecule (e.g., quinine), or the amino acid (e.g., tryptophan).
  • a change in the absorbance of the quinine is reflective of a change in the small molecule.
  • the color change between the photosensitive material and the measure of the degradation of the sample may not be the same for all characteristics examined, it is true that there is a direct relationship between the change in color of the photosensitive material and the measure of the degradation of the active ingredient, such that the photosensitive material may be used as a real-time indicator for changes occurring to an active ingredient in a container.
  • the use of a correlation between the degradation of the material (e.g., polypeptide) disposed within the interior chamber 114 and the property (e.g., color) change of the photosensitive layer 140 as a real-time indication and indicator of the changes and/or degradation of the material within the interior chamber 114 provides a number of opportunities for optimization of the product 100 through selection of the photosensitive material for the layer 140. A number of factors may also need to be accounted for in providing a stabile and reliable indication and indicator. Certain examples of opportunities for optimization and factors to be accounted for are provided herein; the list is not intended to be exhaustive.
  • the photosensitive material may be selected to be responsive only to light of that wavelength or to range of wavelengths.
  • the sensitivity of the material to the wavelength of interest may be selected so as to match or relate a more sensitive (reactive) material for the photosensitive layer 140 with a more sensitive (reactive) material (e.g., a more sensitive polypeptide) disposed within the container 110 relative to the wavelength under consideration.
  • the material (e.g., polypeptide) within the interior chamber 114 may experience degradation as a consequence of a number of reactions, each of which is attributable to light of a different wavelength. It may be the case that all of these factors contribute to the reduced efficacy of the material for treatment of a particular medical condition, and no one factor predominates. Based on this analysis, a photosensitive material reactive to a wide range of wavelengths may be used for the layer 140.
  • the material or substance (e.g., polypeptide) in the interior chamber 114 may exhibit degradation when exposed to a light over a particular range of wavelengths, it may be possible that the environment will selectively eliminate or provide only certain wavelengths within that range. As a consequence, rather than selecting a material based on the entire range of wavelengths known to cause degradation of the material disposed within the interior chamber 114, the photosensitive material may be selected according to the wavelengths known to exist within a given environment.
  • the photosensitive material selected for a layer 140 applied to a container 110 that will predominantly be used within a manufacturing facility, such as a carboy, may differ from the photosensitive material selected for a layer 140 applied to a container 110 that will be carried by paramedics or the like for use in the field.
  • Fig. 15 illustrates the change in colorimeter readings for a photosensitive material that may be used in the layer 140 over a range of light exposures and a plurality of temperatures. It may be observed from Fig. 15 that the change in colorimeter reading may vary less dramatically at lower temperatures (e.g. 4°C) than at higher temperatures (37°C).
  • the material for the layer 140 may also be selected according to the performance characteristics of the photosensitive material over the operational range of temperatures expected.
  • the knowledge of variations in colorimeter readings based on temperature may be used to create corrections for correlations between the changes in the material of the layer 140 and the changes in the material in the container 110 that are temperature dependent, which further corrections may enhance the stability and reliability of the correlations.
  • Figs. 28 and 29 illustrate that little reversibility is believed to exist in the color change of photosensitive material that has been exposed and then subsequently stored in a space without further light exposure (i.e., in the dark) over a wide range of
  • the size and placement of the layer 140 may also be selected to improve the stability of the readings. This in turn may affect the reliability of the derived correlation, as well as reliability of an assessment of the condition of the material (e.g., polypeptide) in the chamber 114 made in reliance on the correlation.
  • readings obtained from a layer 140 that is planar or appears substantially planar relative to the measuring device or equipment used to take the color reading of the layer 140 may be more consistent than readings obtained from a layer 140 with a curved profile.
  • FIG. 1 As a consequence of these various considerations and factors, while an exemplary embodiment has been illustrated in Fig. 1 in which a single layer 140 of material is disposed on the exterior surface 112 of the container 110, more than one layer of material may be disposed on the exterior surface 112 of the containerl 10, or may be associated with the container 110, as explained in greater detail below.
  • each layer may be useful in determining exposure to a different wavelength of light, may have different sensitivity to temperature, or may be of different sizes and shapes.
  • the presence of multiple layers 140 on a single container 110 may lead to user confusion in certain circumstances, so the layers 140 may be disposed on portions of the exterior surface 112 of the container 110 remote from each other, or in such a manner that at least one of the layers 140 may be removed from the exterior surface 112, for example, once the photosensitive material in the layer no longer is capable of undergoing a property change, e.g., a colorimetrically detectable property change.
  • the layer 140 may be exposed to environmental conditions contemporaneous with the polypeptide being disposed in the interior chamber 114. That is, the layer 140 may be disposed on the exterior surface 112 of the container 110 and exposed to the same conditions the material (e.g., polypeptide) is exposed to at the same time the material is disposed into the interior chamber 114 of the container 110, or within some time period before or after the material is disposed into the chamber 114.
  • the length of the time period considered to be contemporaneous may be determined by the sensitivity of the material in the chamber 114 and/or the sensitivity of the material used to define the layer 140, for example.
  • the layer 140 may be exposed to environmental conditions at some point in time that is not considered contemporaneous with the material (e.g., polypeptide) being disposed in the interior chamber 114. Where the reaction of material disposed within the container 110 happens rapidly, even the passage of a limited period of time may be considered to be non-contemporaneous. However, in more general terms, this may encompass a situation wherein the layer 140 is purposefully shielded from exposure to the same conditions as the material disposed in the chamber 114, for example through the use of a physical barrier or photoresistive material.
  • the material e.g., polypeptide
  • the label 160 may include a substrate 162 having a first surface 164 and a second surface 166, which surfaces 164, 166 are disposed on opposite sides of the substrate 162.
  • the size of the substrate 162 relative to the size of the layer 140 has been purposely exaggerated in Fig. 1 so that the substrate 162 may be more easily visualized and identified.
  • the layer 140 extends to the edges of the substrate 162; however, it is possible for the edges of the layer 140 to be spaced from the edges of the substrate 162 as shown. Also, a corner of the substrate 162 is turned back in Fig. 1 to expose the surface 166, although this corner would typically lie along the surface 112 as assembled.
  • the substrate 162 may be a paper product, but also may be made of plastic or other polymer, for example. On one surface (surface 166, as illustrated) may be disposed an adhesive or other compound that may be used to affix, adhere or attach the label 160 to the surface 112.
  • the substrate 162 may be attached to the exterior surface 112 by applying a material over the surface 164 of the label, which material would be selected to be sufficiently transparent such that the layer 140 may be visualized or scanned and such that the operation of the layer 140 (i.e., the photosensitivity of the layer 140) would not be affected.
  • a clear, single-side tape product may be used to attach the substrate 162 (and thus the label 160) to the surface 112.
  • the application of additional layer may not only attach the substrate 162 to the surface 112, but may protect the layer from environmental conditions (e.g., humidity) as well; consequently, the additional layer may be present even when not used to attach the substrate 162 to the surface.
  • the use of an adhesive-backed label 160 may also facilitate the assembly of the product 100 including the label 160 during manufacturing.
  • Fig. 16 illustrates an embodiment wherein the layer 140 of photosensitive material is applied directly to the exterior surface 112 of the container 110.
  • the surface 112 may need to be prepared prior to application of the layer 140 to the surface 112.
  • the preparation of the surface 112 may require the application of other chemicals to the surface 112 to permit a satisfactory joining or bonding to occur between the material of the layer 140 and the material of the container 110. It will be recognized that while such chemicals may technically present an intermediate layer between the layer 140 and the surface 112 of the container 110, the layer 140 may still be understood as being applied to the surface 112 of the container 110 for the purposes of this disclosure.
  • the label 160 may also include other elements beyond the layer 140.
  • the label 160 may include indicia to identify the material (e.g., polypeptide) disposed within the chamber 114, such as the name of the material, the name of the manufacturer, instructions relating to use of the material, etc.
  • the label 160 may include indicia relevant to the layer 140, such as a color scale, so that a user would know without further reference to additional materials how to interpret the layer 140 so as to know if the material (e.g., polypeptide) within the chamber 114 should be safe to administer or not. This color scale may be based on the correlations between the changes in the material of the layer 140 and in the material in the chamber 114 discussed above.
  • the label 160 may also include other structures that cooperate with the layer 140.
  • the layer 140 may be shielded or concealed from exposure to light. Consequently, Fig. 17 illustrates a label 160 including the substrate 162 on which the layer 140 is disposed, and a further layer 180 of removable photo-resistive material applied over the layer 140 of photosensitive material.
  • the photo-resistive material of the layer 180 may block all light exposure; according to other embodiments, the photo-resistive material of the layer 180 may block only a portion of the light exposure.
  • the layer 180 of removable photo-resistive material comprises a cover removably attached to the exterior surface 112 of the container 110 over the layer 140 of photosensitive material to block light of all wavelengths, and may be made of coated paper, coated plastic, or metallic (e.g., aluminum) foil having a releasable adhesive applied to at least a portion of the surface 182 facing the layer 140.
  • This cover 180 may be removed as required. While the cover 180 may be removably attached directly to the exterior surface 112 of the container 110 according to certain embodiments, according to the embodiment illustrated in Fig. 17, the cover 180 is removably attached to the substrate 162, which is in turn disposed on the surface 112 of the container 110.
  • the label 160 has a first region 190 disposed on the exterior surface 112 of the container 110 with a layer 191 of photosensitive material applied thereto and a second region 192 removably disposed on the exterior surface 112 of the container 110 with a layer 193 of the photosensitive material applied thereto.
  • the first region 190 and the second region 192 of the label may be integrally attached (i.e., formed as a single piece), but the boundary between the first and second regions 190, 192 may be defined by a perforation 194, which may facilitate the separation of the first and second regions 190, 192.
  • the boundary between the first and second regions 190, 192 may simply be defined by a marking on the label 160.
  • the first and second regions 190 are identical to the first and second regions 190,
  • the layer 191 and the layer 193 should experience roughly the same exposure to light as the material in the chamber 114. Therefore, the regions 190, 192 and the respective layers 191,
  • a label 160 such as the one illustrated in Fig. 18 may be used, consider that while the container 110 may be used for storage of the material, it is likely that the material will be removed from the container 110 and disposed in a delivery device before the material is administered to the patient.
  • the container 110 is a single-dose vial
  • the material disposed in the container 110 may be removed from the container using a syringe 200 with a needle (see Fig. 19) or a syringe with a luer tip and a vial adapter. In either case, it may be some time before the material in syringe is administered to the patient.
  • the exposure to light will continue throughout this time, it may be advantageous to continue the monitoring of the light exposure by removing the second region 190 of the label 160, and attaching the second region 192 to the syringe 200, such that the layer 193 may be observed.
  • the monitoring of the light exposure of the material in the syringe 200 may continue even after the material is removed from the container 110 using such a system.
  • the label 160 includes a substrate 162 having a first portion 190 and a second portion 192, each with its respective layer 191, 193 of photosensitive material.
  • a cover 210 in Fig. 21 is disposed over the layer 193 arranged on the second portion 192 of the substrate 162.
  • This cover 210 may be similar in nature to the cover 182 discussed above in that the cover 210 may be defined by a layer of photo-resistive material removably attached to the exterior surface 112 of the container 110 over the layer 193 of photosensitive material. As illustrated, the cover 210 may be removably attached to the portion of the substrate 162 that defines the second portion 192 of the label, such that the second section 192 and the cover 210 may be removed as a single item from the container 110.
  • the label illustrated in Fig. 20 may be used in a fashion similar to that of the label illustrated in Figs. 18 and 19. That is, when the material in the chamber 114 of the container 110 is transferred to a syringe 220 (see Fig. 21), the second section 192 and the cover 210 may be removed from the container 110 and applied to the syringe 220. The cover 210 may then be removed from the second section 192 of the label 160 to expose the layer 193 of photosensitive material beneath the cover 210. The monitoring of the light exposure of the material in the syringe 220 may thus continue with the layer 193. It will be recognized that a similar effect may be achieved if the cover 210 is first removed from the second section 192 of the label 160 (and thus the layer 193) prior to application of the second section 192 to the syringe 220.
  • a label such as that illustrated in Figs. 20 and 21 may be advantageous, for example, when the material used to make the container 110 has a filtering or a blocking effect on the light to which the container 110 is exposed, but that same material is not used in the manufacture of the syringe 220.
  • the cover 210 is removed
  • Figs. 22 and 23 illustrate a container 250 in which a polypeptide, for example, is disposed.
  • the container 250 is used in conjunction with a label or labeling system that permits monitoring of light exposure and temperature, for example.
  • a label or labeling system that permits monitoring of light exposure and temperature, for example.
  • the polypeptide has a photosensitive property that changes based on exposure to light having a wavelength within the range between X and Y, and also has a temperature-sensitive property.
  • the temperature-sensitive layer may be used to signal the user to use a different correlation for the photosensitive layer 252 where the photosensitive material of the photosensitive layer 252 is temperature- sensitive (see Fig. 15, above).
  • a layer 252 of photosensitive material may be disposed on an exterior surface 254 of the container 250 and exposed to environmental conditions contemporaneous with the polypeptide being disposed in the interior chamber, for example.
  • the photosensitive material may be reactive to light having a wavelength within the range between X and Y to experience a property change at a threshold of cumulative exposure to light received within the range between X and Y related to the change in the photosensitive property of the polypeptide. It will be recognized that any of the variations in regard to the layer of photosensitive material illustrated and/or discussed above may be used in conjunction with the layer 252.
  • a label 256 including a layer 258 of temperature sensitive material may be disposed on the exterior surface 254 of the container 250.
  • the layer 258 may experience a property change (e.g., a colorimetrically detectable property change) at a threshold of temperature exposure related to a change in a temperature- sensitive property of the material in the container 250, i.e., the polypeptide according to the present embodiment.
  • This layer 258 may be disposed on or against a background 260 of varying colors to facilitate detection or visualization of the change of the layer 258 (compare Fig. 22 to Fig. 23, for example).
  • a similar mechanism may be used in combination with the layer of photosensitive material, in this or the other embodiments described herein, to facilitate detection or visualization of the property change of the photosensitive material wherein this property change is a color change.
  • one use that may be made of the product according to the present disclosure is to determine the status of a material disposed in the chamber 114 in real time. This determination may be made, for example, once a correlation has been defined between the property change of the material in the layer 140 and the photosensitivity of the material in the chamber 114. Once known, the correlation may be used to define a scale (e.g., a color scale) that will permit inspection of the layer 140 to be used to determine that status of the material disposed in the chamber 114.
  • a scale e.g., a color scale
  • the correlation may be determined, for example, by disposing material in the chamber 114 contemporaneous with disposing a label 160 on the exterior surface 112 of the container 110, monitoring both the property change of the material in the layer 140 and the photosensitive property of the material in the chamber 114, for example, at a series of time increments over a test period, and collecting the data.
  • the data collected for the material in the layer 140 and for the material in the chamber 114 may be compared, and a correlation or relationship may be defined. Based on the defined relationship, a scale may be determined to permit a level of light exposure for the material in the chamber 114 to be identified with changes in the property of the material in the layer 140 for real-time assessment of the status of the substance in the chamber 114.
  • the monitoring and/or determination of the change in the property of the photosensitive material in the layer 140 will vary according to the material used. For example, if the photosensitive material in the layer 140 experiences a color change, then the change in the property may be determined visually by the user or by an optical colorimetric sensing device, such described above.
  • the optical sensing device may be coupled to a computerized system, which system may be programmed with the correlation or relationship between the property change and the status of the material (e.g., polypeptide) in the chamber 114, and which system may be further programmed to remove a container from inventory if the determination of status suggests that the material is no longer safe and/or effective to administer.
  • the pharmaceutical product thus described may also be used in a method of confirming correct handling of photosensitive material (e.g., polypeptide) in the container.
  • the layer 140 of photosensitive material would be applied to the exterior surface 112 of the container 110 having the polypeptide or other material disposed therein, the polypeptide or other material having a photosensitive property that changes based on at least cumulative exposure to light having a wavelength within the range between X and Y and the photosensitive material reactive to light having a wavelength within the range between X and Y to experience a property change (e.g., a colorimetrically detectable property change) at a threshold of cumulative exposure to light received within the range between X and Y related to the change in the photosensitive property of the polypeptide.
  • the container 110 would then be delivered to and collected from a recipient within the
  • the layer of photosensitive material may be examined to determine if the photosensitive material has experienced the property change, and the container may be identified as mishandled if the photosensitive material has experienced the property change.
  • the product 100 may be packaged within a box or wrapper that is intended to be removed only when the material in the container 110 is to be administered to the patient.
  • the box or packaging may be used to limit the light exposure of the material in the container 110. If, however, the layer 140 has undergone a colorimetrically detectable property change, this may be suggestive of the fact that the product 100 has been prematurely taken out of the protective packaging in contravention of the express instructions.
  • the embodiments illustrated in Figs. 1-23 relate to products where in the photosensitive layer is disposed on the exterior surface of the container, it is also possible to dispose the photosensitive layer within the interior chamber of the container, as mentioned in the introductory paragraphs.
  • a pharmaceutical product 300 is illustrated, the product 300 including a container 310 having an interior chamber 314, the container 310 constructed from a material that is photo-resistive.
  • the material may filter or block light of one or more ranges of wavelengths.
  • the exposure of a material disposed in the chamber 314 of the container 310 may be different than if the material was exposed to environmental conditions.
  • the product may also include a layer 340 of photosensitive material disposed in the interior chamber 314 of the container 310.
  • the layer 340 may be disposed on monitoring card 360 including a substrate 362 having a first side 364 and a second side 366.
  • the material may be applied to both sides 364, 366 of the substrate 362.
  • the substrate 362 may be made of a rigid material, such as a rigid cardstock or plastic, which will permit the substrate 362 to remain upright within the chamber 314 when the container 310 is placed on a surface, thereby facilitating the readability of the layer 340.
  • the surface 366 may have an adhesive applied thereto, and the card 360 may be attached at a particular location within the chamber 314.
  • the material of the layer 340 may be a photosensitive material reactive to light having a wavelength within the range between X and Y to experience a property change at a threshold of cumulative exposure to light received within the range between X and Y related to the change in a photosensitive property of a polypeptide. While the polypeptide or other material may be disposed in the chamber 314 with the card 360, it may also be the case that the card 360 is disposed within the chamber 314 without the material also being present in the chamber 314.
  • the card 360 may be disposed in the chamber 314 of the container 310, and then the container 310 may be exposed to a light source of interest.
  • the card 360, and in particular the layer 340 may be monitored for changes as to the property change (e.g., a colorimetrically detectable property change) while exposed to the light.
  • the correspondence of the property change of the layer 340 may be collected, for example, at a series of time increments over a test period.
  • the collected data may be used for a variety of uses. For example, data collected may be compared with data collected with the instance of the card 360 disposed in another container 310 made of another material for which the photo- resistivity is known (perhaps, at least relative to the photo-sensitivity of the material that will be disposed in the chamber 314 is known). Based on the comparison, a determination may be made either to use the material for the container 310 or not to use the material for the container 310.
  • Fig. 25 illustrates an example where a system similar to that illustrated in Fig. 24 was used to measure light exposure (as reflected in colorimeter readings) for a variety of materials: glass, polycarbonate, and Teflon.
  • the lowest plot of data points corresponds to the card 360 disposed in a glass vial, while the upper two plots correspond to the cards disposed in containers of polycarbonate and Teflon.
  • the upper two plots correspond to the cards disposed in containers of polycarbonate and Teflon.
  • the material may be disposed in the chamber 314 at the same time as the card 360, and both the property change of the material in the layer 340 and the photosensitive property of the material in the chamber 314 may be monitored and collected, for example, at a series of time increments over a test period.
  • the data collected for the material in the layer 340 and for the material in the chamber 314 may be compared, and a correlation or relationship may be defined. Based on the defined relationship, a scale may be determined to permit a level of light exposure for the material in the chamber 314 to be identified with changes in the property of the material in the layer 340.
  • Still another system and use for the present technology may be described according to the schematic of a facility, such as a manufacturing facility for example, according to Fig. 26, and may involve a system and method for analyzing light exposure of a pharmaceutical product passing through the facility.
  • This system and use may be particularly helpful when and where it is not possible to limit the light exposure of the product passing through the facility because of regulatory directives, for example.
  • European Council Directive 89/654/ECC (of Nov. 30, 1989) requires that workplaces must, as far as possible, receive sufficient natural light and be equipped with artificial lighting adequate for protections of workers' safety and health. As such, it may not be possible to limit light exposure to the product, and yet comply with the light requirements of the Council Directive relative to the workers' safety and health.
  • the manufacturing facility or plant 400 may include at least one space (according to the illustrated embodiment of Fig. 26, a plurality of spaces) through which a pharmaceutical product according to the present disclosure may pass. These spaces may be physically separated from each other through the presence of walls or other barriers; in other instances, the spaces may be demarked from an organizational standpoint, but there may no physical barrier demarking one space, area or region from the other.
  • the product may include a label as according to any of the preceding embodiments. However, in addition to such a label affixed to the pharmaceutical product, additional photosensitive devices 402, or phototrackers, may be disposed about the plant 400 once a path P along which the product passes through the plant has been identified. The information regarding light exposure developed through the use of the devices 402 may be used in conjunction with information from the labels associated with the product, or may be used separately instead.
  • the plant 400 includes a first space 410, wherein the pharmaceutical product is prepared.
  • a polypeptide that represents the active component in the product may be combined within the space 410 with a media in which the polypeptide will be stored and administered to a patient.
  • polypeptide may have a photosensitive property that changes based on at least cumulative exposure to light having a wavelength within the range between X and Y.
  • the active component and the media may be disposed in a container such as that illustrated in Fig. 2 at this time.
  • the active component and the media may then pass from the space 410 into space 412, wherein the active component and media is filled into a smaller containers, such as those illustrated in Fig. 1.
  • the filled containers may then pass into a transfer space 414 before moving to an inspection space 416 or a storage (or warehouse) space 418.
  • product may flow from the filling space 410 directly through the transfer space 414 to the inspection space 416, or may detour through the storage space 418. Additionally, before moving along the path P from the inspection space 416, the product may be returned to the warehouse space 418.
  • the product may be assembled with other items to define a system or a kit within assembly space 420. As illustrated, the product may arrive at assembly space 420 either from the inspection space 416 or the warehouse space 418.
  • the product may be combined with a syringe, such as is illustrated in Figs. 19 or 21, to define a system or to be packaged as part of a kit, in an injection kit clam shell, for example.
  • the product may be assembled as part of system in the form of a medical device, such as an autoinjector (as illustrated in Figs. 22 and 23),
  • the system or kit may pass through a loading dock 422, prior to removal from the plant 400.
  • devices 402 are disposed along the path P that the product takes through the spaces 410, 412, 414, 416, 418, 420, 422.
  • the devices 402 may include a layer of photosensitive material reactive to light having a wavelength within the range between X and Y to experience a property change (e.g., a colorimetrically detectable property change) at a threshold of cumulative exposure to light received within the range between X and Y.
  • a property change e.g., a colorimetrically detectable property change
  • the number of devices may differ between spaces, such that spaces 414, 416 have only a single device, while spaces 410, 412 have two devices, space 420 has three devices, space 422 has four devices, and space 418 has six devices.
  • the devices 402 may be attached through the use of an adhesive backing, for example, to particular structures, equipment or machinery disposed within the spaces 410-422, such as mixing tanks or syringe/cartridge filling machines for example.
  • the placement and number of devices used may be dictated by a number of factors. For example, in certain rooms, certain equipment or other environmental light sources (lamps, overhead lighting, windows, etc.) may be disposed primarily to one side of the path or the other. Additionally, it may be more desirable to place additional devices in a larger room, or a room in which the path has multiple entry and exit points, or a more complex path. For example, space 418 might qualify under all of these criteria for the inclusion of more devices 402 that in other spaces.
  • the phototrackers or photosensitive devices 402 Disposing the devices 402 along the path P permits identification and isolation of points along the path P at which light of a particular wavelength or intensity impacts the product. Through the use of the devices 402, this identification and isolation may be performed in real time.
  • the photosensitive devices 402 may be read for evidence of a property change using an optical sensing device proximate to the device 402, the optical sensing device coupled to a computing device that displays an indication of light exposure experienced by the at least one device 402.
  • a label affixed to a product may be used to determine the cumulative exposure of the individual product, and as a consequence whether the product should be used or discarded.
  • the label will not provide a history of where the product has received the exposure that has been recorded through the use of the label on the product. Even if a label attached to a product were to be inspected for cumulative light exposure at various points along the path P, using the light exposure information obtained in this fashion may still make identification and isolation of a localized spaces, areas or regions of increased light exposure or light exposure of particular wavelengths difficult. This is particular true given that certain spaces, such as space 420, may have product passing through it after having passed through any of a number of preceding spaces, because of the manner in which product may be transported between the transfer, inspection and warehouse spaces 414, 416, 418.
  • the light exposure of the product within the plant 400 may be analyzed separately from the product itself, and considered without having to account for the movement of the product along the path P.
  • readings obtained from the devices 402 disposed in the space 418 suggest that product moving along the path P are exposed to considerable amounts of light having a wavelength or wavelengths of interest relative to that product in the portion of the space where the product is stored between the inspection and assembly spaces 416, 420.
  • Additional devices 402 may then be disposed in the space 418 to further identify the source of the light, or along alternative paths within the space 418 to determine the viability of these alternative paths for the product prior to modification of the path P within the space 418. If the labels were used only on the product, the identification of such sources or alternative paths may only occur through the exposure of additional amounts of light exposure that may result in the degradation of the product and the need for its disposal.
  • Fig. 27 illustrates the range and nature of color change possible for five different sensitivities of a material that may be used in the devices 402 when exposed to varying amounts of visible light, the color change being measured according to the L*a*b index. It will also be recognized that the use of this system and method is not limited to a production facility, but might be used in other buildings or structures as well, such as a healthcare facility, testing lab, hospital or clinic.
  • the devices according to the present disclosure may have one or more advantages relative to conventional technology, any one or more of which may be present in a particular embodiment in accordance with the features of the present disclosure included in that embodiment. Other advantages not specifically listed herein may also be recognized as well.

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Details Of Rigid Or Semi-Rigid Containers (AREA)
  • Packages (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

La présente invention concerne un produit pharmaceutique comprenant un récipient présentant une surface extérieure et une chambre intérieure, un principe actif disposé dans la chambre intérieure, le principe actif présentant une propriété photosensible qui change en fonction d'au moins l'exposition cumulée à la lumière présentant une longueur d'onde dans la plage entre X et Y, et une couche de matériau photosensible disposée sur ou dans le récipient et exposée aux conditions environnementales contemporaines du principe actif disposé dans la chambre intérieure. Le matériau photosensible est réactif à la lumière présentant une longueur d'onde dans la plage comprise entre X et Y pour établir un changement de propriété à un seuil d'exposition cumulée de lumière reçue dans la plage entre X et Y en fonction du changement de propriété photosensible du principe actif. Un dispositif photosensible peut également être disposé le long d'un trajet suivi par le produit pharmaceutique dans une installation.
PCT/US2012/053450 2011-09-02 2012-08-31 Produit pharmaceutique et procédé d'analyse de l'exposition lumineuse d'un produit pharmaceutique WO2013033600A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EA201490555A EA201490555A1 (ru) 2011-09-02 2012-08-31 Фармацевтический продукт и способ анализа реакции фармацевтического продукта на свет
CN201280041624.7A CN103917458A (zh) 2011-09-02 2012-08-31 药物产品和分析药物产品的光暴露的方法
MX2014002533A MX2014002533A (es) 2011-09-02 2012-08-31 Producto farmaceutico y metodo de analisis de exposicion a la luz de un producto farmaceutico.
AU2012301656A AU2012301656A1 (en) 2011-09-02 2012-08-31 Pharmaceutical product and method of analysing light exposure of a pharmaceutical product
EP12769524.5A EP2750989A1 (fr) 2011-09-02 2012-08-31 Produit pharmaceutique et procédé d'analyse de l'exposition lumineuse d'un produit pharmaceutique
KR1020147008727A KR20140058669A (ko) 2011-09-02 2012-08-31 의약품 및 의약품의 광 노출을 분석하는 방법
BR112014004591A BR112014004591A2 (pt) 2011-09-02 2012-08-31 produto farmacêutico de análise da exposição à luz de um produto farmacêutico
US14/241,882 US20140315187A1 (en) 2011-09-02 2012-08-31 Pharmaceutical Product and Method of Analysing Light Exposure of a Pharmaceutical Product
CA2840637A CA2840637A1 (fr) 2011-09-02 2012-08-31 Produit pharmaceutique et procede d'analyse de l'exposition lumineuse d'un produit pharmaceutique
ZA2013/09704A ZA201309704B (en) 2011-09-02 2013-12-20 Pharmaceutical product and method of analysing light exposure of a pharmaceutical product

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530824P 2011-09-02 2011-09-02
US61/530,824 2011-09-02

Publications (1)

Publication Number Publication Date
WO2013033600A1 true WO2013033600A1 (fr) 2013-03-07

Family

ID=46982918

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/053450 WO2013033600A1 (fr) 2011-09-02 2012-08-31 Produit pharmaceutique et procédé d'analyse de l'exposition lumineuse d'un produit pharmaceutique

Country Status (13)

Country Link
US (1) US20140315187A1 (fr)
EP (1) EP2750989A1 (fr)
JP (1) JP2014529473A (fr)
KR (1) KR20140058669A (fr)
CN (1) CN103917458A (fr)
AU (1) AU2012301656A1 (fr)
BR (1) BR112014004591A2 (fr)
CA (1) CA2840637A1 (fr)
CL (1) CL2014000104A1 (fr)
EA (1) EA201490555A1 (fr)
MX (1) MX2014002533A (fr)
WO (1) WO2013033600A1 (fr)
ZA (1) ZA201309704B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202785A1 (fr) 2015-06-17 2016-12-22 Novozymes A/S Contenant

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL250601B (en) * 2017-02-14 2018-05-31 Marpaz Tech Ltd Container for light sensitive material
WO2020172257A1 (fr) * 2019-02-22 2020-08-27 The Chemours Company Fc, Llc Procédés de détermination de propriétés photosensibles d'un matériau

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0117390A2 (fr) * 1983-02-25 1984-09-05 Lifelines Technology, Inc. Procédé de surveillance de l'exposé incrémental à l'environnement des produits, subissant des changements de qualité progressifs suite aux stimulations extérieures
US4695623A (en) 1982-05-06 1987-09-22 Amgen Consensus human leukocyte interferon
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
EP0367566A1 (fr) 1988-10-31 1990-05-09 Immunex Corporation Récepteurs d'interleukine-4
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
EP0460846A1 (fr) 1990-06-05 1991-12-11 Immunex Corporation Récepteurs de type II de l'interleukine 1
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
WO1994010308A1 (fr) 1992-10-23 1994-05-11 Immunex Corporation Procede de preparation de proteines oligomeres solubles
WO1994028391A1 (fr) 1993-05-24 1994-12-08 Immunex Corporation Ligands pour les recepteurs flt3
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
WO1997001633A1 (fr) 1995-06-29 1997-01-16 Immunex Corporation Cytokine inductrice d'apoptose
US5610279A (en) 1989-09-12 1997-03-11 Hoffman-La Roche Inc. Human TNF receptor
US5767064A (en) 1990-06-05 1998-06-16 Immunex Corporation Soluble type II interleukin-1 receptors and methods
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US6015938A (en) 1995-12-22 2000-01-18 Amgen Inc. Osteoprotegerin
WO2000024782A2 (fr) 1998-10-23 2000-05-04 Amgen Inc. Peptides modifies utilises comme agents therapeutiques
US6087329A (en) 1991-10-25 2000-07-11 Immunex Corporation CD40 ligand polypeptide
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO2001036637A1 (fr) 1999-11-17 2001-05-25 Immunex Corporation Activateur du recepteur de nf-kappa b
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
WO2001083525A2 (fr) 2000-05-03 2001-11-08 Amgen Inc. Peptides modifies utilises comme agents therapeutiques
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06174600A (ja) * 1992-09-16 1994-06-24 Caterpillar Inc 状態変化を表示する方法および装置

Patent Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695623A (en) 1982-05-06 1987-09-22 Amgen Consensus human leukocyte interferon
US4897471A (en) 1982-05-06 1990-01-30 Amgen Consensus human leukocyte interferon
EP0117390A2 (fr) * 1983-02-25 1984-09-05 Lifelines Technology, Inc. Procédé de surveillance de l'exposé incrémental à l'environnement des produits, subissant des changements de qualité progressifs suite aux stimulations extérieures
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
EP0367566A1 (fr) 1988-10-31 1990-05-09 Immunex Corporation Récepteurs d'interleukine-4
US5856296A (en) 1988-10-31 1999-01-05 Immunex Corporation DNA encoding interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5610279A (en) 1989-09-12 1997-03-11 Hoffman-La Roche Inc. Human TNF receptor
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5767064A (en) 1990-06-05 1998-06-16 Immunex Corporation Soluble type II interleukin-1 receptors and methods
EP0460846A1 (fr) 1990-06-05 1991-12-11 Immunex Corporation Récepteurs de type II de l'interleukine 1
US6087329A (en) 1991-10-25 2000-07-11 Immunex Corporation CD40 ligand polypeptide
WO1994010308A1 (fr) 1992-10-23 1994-05-11 Immunex Corporation Procede de preparation de proteines oligomeres solubles
WO1994028391A1 (fr) 1993-05-24 1994-12-08 Immunex Corporation Ligands pour les recepteurs flt3
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
WO1997001633A1 (fr) 1995-06-29 1997-01-16 Immunex Corporation Cytokine inductrice d'apoptose
US6015938A (en) 1995-12-22 2000-01-18 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2000024782A2 (fr) 1998-10-23 2000-05-04 Amgen Inc. Peptides modifies utilises comme agents therapeutiques
WO2001036637A1 (fr) 1999-11-17 2001-05-25 Immunex Corporation Activateur du recepteur de nf-kappa b
WO2001083525A2 (fr) 2000-05-03 2001-11-08 Amgen Inc. Peptides modifies utilises comme agents therapeutiques

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
"Growth Factors: A Practical Approach", 1993, OXFORD UNIVERSITY PRESS INC.
"Human Cytokines: Handbook for Basic and Clinical Research", vol. II, 1998, BLACKWELL SCIENCES
"Proceedings of the VIth International Workshop and Conference", 1996
"The Cytokine Handbook", 1991, ACADEMIC PRESS
"Yellowness Indices", vol. 8, 2008, HUNTER ASSOCIATES LABORATORY INC. OF RESTON, VIRGINIA
BRUCE KERWIN; RICHARD REMMELE: "Protect from light: Photodegradation and protein biologics", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 96, June 2007 (2007-06-01), pages 1468 - 80
DO; CHEN-KIANG, CYTOKINE GROWTH FACTOR REV., vol. 13, no. 1, 2002, pages 19 - 25
HAKANSSON ET AL., STRUCTURE, vol. 7, 1999, pages 255 - 64
HARBURY ET AL., NATURE, vol. 371, 1994, pages 80 - 83
HARBURY ET AL., SCIENCE, vol. 262, 1993, pages 1401 - 05
LOVEJOY ET AL., SCIENCE, vol. 259, 1993, pages 1288 - 1293
MAISONPIERRE ET AL., SCIENCE, vol. 277, no. 5322, 1997, pages 55 - 60
RÜEGG; PYTELA, GENE, vol. 160, 1995, pages 257 - 62

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016202785A1 (fr) 2015-06-17 2016-12-22 Novozymes A/S Contenant
CN107922095A (zh) * 2015-06-17 2018-04-17 诺维信公司 容器
US10717576B2 (en) 2015-06-17 2020-07-21 Novozymes A/S Container for polypeptide

Also Published As

Publication number Publication date
MX2014002533A (es) 2014-08-26
AU2012301656A1 (en) 2014-01-16
JP2014529473A (ja) 2014-11-13
CA2840637A1 (fr) 2013-03-07
EP2750989A1 (fr) 2014-07-09
CL2014000104A1 (es) 2014-07-25
KR20140058669A (ko) 2014-05-14
EA201490555A1 (ru) 2014-07-30
CN103917458A (zh) 2014-07-09
ZA201309704B (en) 2014-08-27
US20140315187A1 (en) 2014-10-23
BR112014004591A2 (pt) 2017-03-28

Similar Documents

Publication Publication Date Title
Beck et al. Macro-and micro-heterogeneity of natural and recombinant IgG antibodies
EP2807190B1 (fr) Formulations stabilisées contenant des anticorps anti-ang2
Visser et al. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab
Boulet-Audet et al. High-throughput thermal stability analysis of a monoclonal antibody by attenuated total reflection FT-IR spectroscopic imaging
EP1977241B1 (fr) Dosage de la cytotoxicité cellulaire dépendant des anticorps
Shi et al. Recognition of human IgG1 by Fcγ receptors: structural insights from hydrogen–deuterium exchange and fast photochemical oxidation of proteins coupled with mass spectrometry
ES2905615T3 (es) Sistemas y métodos para evaluar moduladores de puntos de control inmunitario
US20140315187A1 (en) Pharmaceutical Product and Method of Analysing Light Exposure of a Pharmaceutical Product
US20170210821A1 (en) Antibodies that Recognize Red Blood Cell Antigens
Kagdi et al. Determination of holdup volume and transient contact compatibility of closed system transfer devices for a reconstituted lyophilized drug product
Kuhne et al. The impact of immunoglobulin G1 Fc sialylation on backbone amide H/D exchange
Schreiber et al. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
WO2019106592A2 (fr) Dosages immunologiques et protéines modifiées pour la surveillance de traitements par anticorps contre les inhibiteurs de points de contrôle immunitaires pd1 et pd-l1
Ambrogelly The different colors of mAbs in solution
Yadav et al. Nonclinical pharmacokinetics and pharmacodynamics characterization of anti-CD79B/CD3 T cell-dependent bispecific antibody using a surrogate molecule: a potential therapeutic agent for B cell malignancies
Gurel et al. Structural and functional analysis of CEX fractions collected from a novel Avastin® Biosimilar candidate and its innovator: a comparative study
IL294765B2 (en) Deglycosylation methods for electrophoresis of glycosylated proteins
JP2022513749A (ja) 勾配によるタンパク質濃度定量を伴う使用のためのシステム適合性方法
TW202016125A (zh) 用於定量及調節蛋白質黏度之系統與方法
Messick et al. Chapter 11: Particles in biopharmaceuticals: causes, characterization, and strategy
Holm An exploratory study of the durability of biopharmaceuticals in AstraZeneca's Quality Control Operations
CA2999866C (fr) Composition et methodes pour evaluer la sensibilite et la specificite de reactifs de detection d'anticorps
Doevendans et al. Protein quality testing in the era of personalized medicine
Desai et al. Feasibility of Laboratory Equipment-Based Simulation Methods to Assess the Impact of Vehicle Transportation on Product Quality of mAb Dosing Solutions
Shibata et al. Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12769524

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2840637

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2014000104

Country of ref document: CL

ENP Entry into the national phase

Ref document number: 2012301656

Country of ref document: AU

Date of ref document: 20120831

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014528661

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/002533

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2012769524

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201490555

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20147008727

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14241882

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014004591

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014004591

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140226

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载